Compugen Enhances its AI/ML Predictive Computational Discovery Platform, Unigen™ with Ultima Genomics' Single Cell Genomics Sequencing Technology

Core Insights - Compugen Ltd. announced a collaboration with Ultima Genomics to enhance its gene sequencing database through the integration of AI/ML powered predictive computational discovery platform, Unigen, and high throughput single cell sequencing technology [1][2] - The collaboration aims to uncover new insights into gene structure for immuno-oncology, with findings presented at the AGBT conference [2][3] - Compugen plans to leverage Ultima's technology to develop proprietary single cell atlases for accelerated discovery of new immunotherapies [2] Group 1: Collaboration and Technology - Compugen's Chief Scientific Officer highlighted the development of algorithms to study gene splicing at single cell resolution, analyzing patient tumor samples to identify potential regulatory mechanisms in immuno-oncology [2] - Ultima Genomics' UG 100 sequencing platform is designed to provide lower cost sequencing and more omics data, facilitating new applications and insights in cancer research [2][6] - The collaboration is expected to transform data-starved applications in immuno-oncology through large-scale data and AI/ML techniques [2] Group 2: Research Findings - A poster presented at the AGBT 2025 meeting detailed the use of 3' single cell sequencing to study patient-derived tumor cells, revealing enhanced potential to study differential splicing at the cell type level [3] - Comparative analysis using tumor samples showed high consistency in single-cell expression levels across Ultima's UG 100 and Illumina's Novaseq 6000 sequencing platforms, with UG 100 providing clearer demarcation of 3' mRNA transcript ends [6] - The gene structure information identified through this approach contributes to the predictive models of Unigen, enhancing the understanding of tumor biology and immune regulation [5][6] Group 3: Company Overview - Compugen is a clinical-stage therapeutic discovery and development company focused on identifying new drug targets and biological pathways for cancer immunotherapies [8] - The company has two proprietary product candidates in Phase 1 development and a bispecific antibody in Phase 3 development through a collaboration with AstraZeneca [8] - Compugen's Unigen platform integrates various biological data, including multi-omics and single-cell RNA sequencing, to discover novel drug targets and understand complex biology [7]